Shots:Novartis has reported that Cosentyx met all 1 & 2 EPs in the P-III trial in adults with PMRThe global P-III (REPLENISH) trial showed that Cosentyx (secukinumab) significantly improved sustained remission at Wk 52 in PMR pts vs PBO, with a reduced steroid dose and a safety profile consistent with prior use. Conducted…
